Valuation: Structure Therapeutics Inc.

Market Cap 3.59B 3.12B 2.92B 2.67B 5.04B 342B 5.11B 34.14B 13.4B 171B 13.48B 13.19B 569B P/E 2026 *
-35.3x
P/E 2027 * -24.3x
Enterprise Value 2.59B 2.24B 2.1B 1.92B 3.63B 246B 3.68B 24.59B 9.65B 123B 9.71B 9.5B 410B EV / Sales 2026 *
67.3x
EV / Sales 2027 * 69,563x
Free-Float
76.06%
Yield 2026 *
-
Yield 2027 * -
1 day+2.12%
1 week+4.17%
Current month+7.28%
1 month-5.87%
3 months+26.19%
6 months-31.21%
Current year-25.90%
1 week 46.58
Extreme 46.575
52.08
1 month 44.8
Extreme 44.8001
57.07
Current year 35.78
Extreme 35.78
94.77
1 year 15.85
Extreme 15.85
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 2022-04-30
Chief Executive Officer 62 2019-04-30
Chief Operating Officer 49 2026-04-14
Director TitleAgeSince
Director/Board Member 62 2019-01-31
Chairman 68 2022-01-18
Director/Board Member 66 2022-03-28
Date Insider Type Main position Quantity % Market Cap.
7/22/26
F-Prime Inc.
OtherCompany 17,452 0.0101%
7/22/26
F-Prime Inc.
OtherCompany 0 0%
7/14/26 Fiscal year

Chief Technology Officer

86,658 0.0620%
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+4.17%+215.97%+94.55% 3.59B
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%+0.96%+29.39%+70.50% 54.05B
-2.76%-3.18%-19.23%-8.73% 23.16B
+30.93%+27.72%+16.51%+492.71% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+1.79%+36.31%-26.13% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-6.07%-4.35%+41.96%+164.37% 14.25B
Average +2.24%+3.70%+63.31%+182.38% 25.26B
Weighted average by Cap. +1.43%+3.68%+45.38%+146.74%

Financials

2026 *2027 *
Net sales 38.46M 33.38M 31.25M 28.59M 53.97M 3.66B 54.68M 366M 143M 1.83B 144M 141M 6.09B 41.67K 36.16K 33.86K 30.97K 58.47K 3.97M 59.24K 396K 155K 1.98M 156K 153K 6.6M
Net income -288M -250M -234M -214M -404M -27.39B -409M -2.73B -1.07B -13.69B -1.08B -1.06B -45.56B -423M -367M -344M -315M -594M -40.31B -602M -4.02B -1.58B -20.14B -1.59B -1.55B -67.03B
Net Debt -1B -872M -817M -747M -1.41B -95.72B -1.43B -9.55B -3.75B -47.83B -3.77B -3.69B -159B -693M -601M -563M -515M -972M -65.98B -985M -6.58B -2.58B -32.97B -2.6B -2.54B -110B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
233
Date Price Change Volume
26-08-06 US$51.47 +1.86% 109,006
26-08-05 US$50.53 +1.79% 713,610
26-08-04 US$49.64 +2.65% 876,827
26-08-03 US$48.36 +0.67% 326,381
26-07-31 US$48.04 -2.89% 407,588
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
50.53USD
Average target price
104.83USD
Spread / Average Target
+107.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock